Amicus Therapeutics Stock Performance
| FOLD Stock | USD 14.29 0.02 0.14% |
On a scale of 0 to 100, Amicus Therapeutics holds a performance score of 16. The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Amicus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amicus Therapeutics is expected to be smaller as well. Please check Amicus Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Amicus Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Amicus Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak essential indicators, Amicus Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.11 | Five Day Return (0.21) | Year To Date Return 0.14 | Ten Year Return 128.64 | All Time Return (0.97) |
1 | Acquisition by Samantha Prout of 32193 shares of Amicus Therapeutics subject to Rule 16b-3 | 12/01/2025 |
2 | Disposition of 11000 shares by Ellen Rosenberg of Amicus Therapeutics at 5.13 subject to Rule 16b-3 | 12/10/2025 |
3 | BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In 4.8 Billion Deal | 12/19/2025 |
4 | Disposition of 71303 shares by Simon Harford of Amicus Therapeutics at 14.25 subject to Rule 16b-3 | 12/26/2025 |
5 | Disposition of 18498 shares by David Clark of Amicus Therapeutics at 14.27 subject to Rule 16b-3 | 01/02/2026 |
6 | Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights | 01/08/2026 |
7 | Assessing Amicus Therapeutics Valuation After Recent Share Price Momentum | 01/09/2026 |
8 | MDGL Secures Exclusive Global Right for MASH Treatment From PFE | 01/12/2026 |
9 | Apellis Stock Crashes 23 percent in a Week Heres What You Should Know | 01/15/2026 |
10 | Manifold Finance Reaches Self Reported Market Cap of 1.10 Million | 01/16/2026 |
11 | Disposition of 75000 shares by Campbell Bradley L of Amicus Therapeutics at 6.1 subject to Rule 16b-3 | 01/20/2026 |
12 | NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies | 01/21/2026 |
13 | How A New Price Target Is Shaping The Amicus Therapeutics Investment Story | 01/22/2026 |
14 | BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility | 01/26/2026 |
| Begin Period Cash Flow | 250.1 M | |
| Total Cashflows From Investing Activities | -560 K |
Amicus Therapeutics Relative Risk vs. Return Landscape
If you would invest 890.00 in Amicus Therapeutics on October 29, 2025 and sell it today you would earn a total of 539.00 from holding Amicus Therapeutics or generate 60.56% return on investment over 90 days. Amicus Therapeutics is currently generating 0.8636% in daily expected returns and assumes 4.1196% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Amicus, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amicus Therapeutics Target Price Odds to finish over Current Price
The tendency of Amicus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 14.29 | 90 days | 14.29 | about 9.96 |
Based on a normal probability distribution, the odds of Amicus Therapeutics to move above the current price in 90 days from now is about 9.96 (This Amicus Therapeutics probability density function shows the probability of Amicus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Amicus Therapeutics has a beta of 0.64. This usually indicates as returns on the market go up, Amicus Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Amicus Therapeutics will be expected to be much smaller as well. Additionally Amicus Therapeutics has an alpha of 0.8056, implying that it can generate a 0.81 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Amicus Therapeutics Price Density |
| Price |
Predictive Modules for Amicus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Amicus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Amicus Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Amicus Therapeutics is not an exception. The market had few large corrections towards the Amicus Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Amicus Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Amicus Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.81 | |
β | Beta against Dow Jones | 0.64 | |
σ | Overall volatility | 2.36 | |
Ir | Information ratio | 0.20 |
Amicus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Amicus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Amicus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Amicus Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 528.29 M. Net Loss for the year was (56.11 M) with profit before overhead, payroll, taxes, and interest of 537.49 M. | |
| Amicus Therapeutics currently holds about 386.84 M in cash with (33.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Zai Lab Is Up 7.9 percent After First-In-China AUGTYRO Approval Across TRK TKI Settings |
Amicus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Amicus Stock often depends not only on the future outlook of the current and potential Amicus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Amicus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 304.4 M | |
| Cash And Short Term Investments | 249.9 M |
Amicus Therapeutics Fundamentals Growth
Amicus Stock prices reflect investors' perceptions of the future prospects and financial health of Amicus Therapeutics, and Amicus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amicus Stock performance.
| Return On Equity | -0.0687 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 4.66 B | ||||
| Shares Outstanding | 313.7 M | ||||
| Price To Earning | (9.18) X | ||||
| Price To Book | 19.43 X | ||||
| Price To Sales | 7.49 X | ||||
| Revenue | 528.29 M | ||||
| Gross Profit | 537.49 M | ||||
| EBITDA | 29.39 M | ||||
| Net Income | (56.11 M) | ||||
| Cash And Equivalents | 386.84 M | ||||
| Cash Per Share | 1.38 X | ||||
| Total Debt | 443.64 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 3.02 X | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | (33.89 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Market Capitalization | 4.48 B | ||||
| Total Asset | 785.03 M | ||||
| Retained Earnings | (2.74 B) | ||||
| Working Capital | 356.03 M | ||||
| Current Asset | 216.6 M | ||||
| Current Liabilities | 73.62 M | ||||
About Amicus Therapeutics Performance
By analyzing Amicus Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Amicus Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amicus Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amicus Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 941.74 | 532.30 | |
| Return On Tangible Assets | (0.09) | (0.09) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.06) | (0.07) | |
| Return On Equity | (0.33) | (0.35) |
Things to note about Amicus Therapeutics performance evaluation
Checking the ongoing alerts about Amicus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amicus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amicus Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 528.29 M. Net Loss for the year was (56.11 M) with profit before overhead, payroll, taxes, and interest of 537.49 M. | |
| Amicus Therapeutics currently holds about 386.84 M in cash with (33.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Zai Lab Is Up 7.9 percent After First-In-China AUGTYRO Approval Across TRK TKI Settings |
- Analyzing Amicus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amicus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Amicus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amicus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amicus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amicus Therapeutics' stock. These opinions can provide insight into Amicus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |